CD22 and AL amyloidosis: Interestingly, the other blood tumor clinical CAR-T target genes, CD22 (in Phase 1 trials) and TNFRSF17 (encoding the BCMA protein and FDA-approved against multiple myeloma), are not essential in any cell line of their respective indications analyzed here.